Viking Therapeutics VKTX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $118.12M-28.8% | $165.81M+65.2% | $100.38M+196% | $33.88M-10.7% | $37.94M+42.2% | ||
| $484.85M-10.2% | $539.93M-12.1% | $614.19M-20.6% | $773.84M-4.9% | $813.92M-7.1% | ||
| $608.21M-15.0% | $715.6M-3.1% | $738.7M-10.7% | $827.02M-4.5% | $866.02M-4.5% | ||
| $608.24M-15.0% | $715.73M-3.2% | $739.42M-10.7% | $827.85M-4.5% | $866.99M-4.5% | ||
| $67.18M+26.2% | $53.25M+1,107% | $4.41M-19.7% | $5.49M-28.7% | $7.7M-21.5% | ||
| $106.33M+38.7% | $76.67M+194% | $26.07M-18.5% | $31.98M+63.4% | $19.57M-28.6% | ||
| $106.33M+38.7% | $76.67M+191% | $26.39M-18.5% | $32.39M+61.3% | $20.08M-28.4% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| -$1.01B-18.7% | -$847.55M-22.9% | -$689.88M-15.2% | -$599.1M-12.3% | -$533.54M-9.4% | ||
| $501.92M-21.5% | $639.06M-10.4% | $713.03M-10.4% | $795.46M-6.1% | $846.92M-3.8% | ||
| $608.24M-15.0% | $715.73M-3.2% | $739.42M-10.7% | $827.85M-4.5% | $866.99M-4.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Viking Therapeutics cover its short-term obligations?
- Its current ratio is 5.72 — current assets exceed current liabilities.
- Where does Viking Therapeutics's balance sheet data come from?
- Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.